Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in refractory metastatic colorectal cancer
NCT02332499Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib in metastatic colorectal cancer (mCRC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2014; status: completed.
02
Drugs
anlotinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02332499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332499.